Service for specialized journalist

Grünenthal Press Releases 2016

Welcome to Grünenthal's Press Overview

16 Nov 2016

Grünenthal has acquired US-based Thar Pharmaceuticals Inc. to expand its development portfolio of treatment options for CRPS (Complex Regional Pain Syndrome), a serious, disabling orphan disease.

Aachen, Germany, and Pittsburgh, PA, USA – 16 November 2016 – Grünenthal, an R&D-driven, privately held international pharmaceutical company with headquarters in Germany, has announced its recent acquisition of Thar Pharmaceuticals, a US-based clinical-stage, specialty pharmaceutical company. Thar Pharmaceuticals focused on transforming IV-only drugs into oral drugs for existing and new indications using its proprietary technology EnhanceTM development platform. With this acquisition, Grünenthal has obtained the worldwide development and commercialization rights for Thar Pharmaceutical’s lead development candidate, T121.

More ...

04 Oct 2016

Gabriel Baertschi takes office as new CEO of Grünenthal Group
as of October 1, 2016

The Grünenthal Group today announces that Gabriel Baertschi has taken office as new CEO of the Grünenthal Group, an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. The company’s Supervisory Board had named Gabriel Baertschi to become Grünenthal’s new CEO in June 2016. Gabriel Baertschi is joining Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where in his last appointment he served as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques who retires at the end of 2016 after 23 years at Grünenthal.

More ...

30 Sep 2016

Grünenthal’s cebranopadol, a novel strong analgesic, meets primary efficacy endpoint in Phase 3 trial in cancer pain

Results to be presented at the 2016 IASP conference

Grünenthal presents data for the first time of its compound cebranopadol in patients with cancer-related pain1. The cebranopadol data is from a Phase 3 randomized, double-blind, double-dummy, active-controlled multiple dose study with patients randomized to either once-daily cebranopadol or twice-daily morphine sulfate PR (prolonged release). Results reached statistical significance for non-inferiority and even superiority for the primary endpoint (average amount of daily rescue medication intake over the last two weeks of the maintenance phase in the trial, p<0.05).

More ...

27 Sep 2016

A research consortium under the direction of Grünenthal will receive a grant of €1.5 million from the European Fund for Regional Development and the Federal State of North Rhein-Westphalia

  • Research grant awarded by Leitmarktwettbewerb LifeSciences.NRW to improve the development of new analgesic drugs
  • The consortium members, founded and led by Grünenthal, are from the University Hospitals of Cologne and Bonn, and a specialist scientific company, Life & Brain

More ...

23 Jun 2016


Aachen/Brussels, 23 June 2016. For the tenth time, young European scientists who have an innovative pain research idea, are called upon to apply for one of the most prestigious and highly regarded pain research grants worldwide: The EFIC-GRÜNENTHAL Grant (E-G-G).

More ...

07 Jun 2016

Grünenthal appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer effective October 1, 2016

Swiss native Gabriel Baertschi follows Prof. Dr. Eric-Paul Pâques who retires after 23 years with the company

Grünenthal Group today announced that its Supervisory Board has named Gabriel Baertschi to become Grünenthal’s new CEO as of October 1, 2016. Gabriel Baertschi will join Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where he currently serves as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques, who has been the CEO of the Grünenthal Group. Grünenthal is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany with affiliates in Europe, Latin America and the U.S. In 2015, Grünenthal achieved revenues of € 1.2 bn.

More ...

02 Jun 2016

Grünenthal and AstraZeneca enter into license agreement for lesinurad in Europe and Latin America

Aachen, June 2, 2016. Grünenthal Group today announced that it has entered into a licensing agreement with AstraZeneca for the exclusive rights to Zurampic™ (lesinurad) in Europe and Latin America. Zurampic™ was approved by the European Medicines Agency (EMA) in February 2016, in combination with a xanthine oxidase inhibitor (XOI), for the treatment of adjunctive hyperuricemia in adult patients with uncontrolled gout.

More ...

11 May 2016

Grünenthal announces exclusive license agreement for commercialization of innovative surgical glue in the EU and Latin America

Agreement underpins Grünenthal’s strategy to strengthen its portfolio for the European hospital market

The Grünenthal Group today announced an exclusive license and supply agreement with Adhesys Medical Inc., USA, on the commercialization of an innovative topical skin adhesive. With this agreement, Grünenthal acquires the exclusive distribution rights for the EU and Latin American markets. Both companies pursue the common objective to launch a medical device that meets highest standards.

More ...

15 Mar 2016

Grünenthal Group to Acquire Almirall de Mexico, S.A. de C.V.

Aachen, Germany and Mexico City, Mexico, March 15, 2016. Grünenthal Group announced today to have entered into a definitive agreement with Almirall Group under which Grünenthal will acquire 100% of the share capital of Almirall de Mexico. The transaction also includes an agreement to perpetually license a portfolio of mainly international products with around 17.5 million Euro net sales in 2015 in Mexico. The transaction will be completed in early May, 2016.

More ...

03 Mar 2016

Drug Discovery Collaboration between Grünenthal and Axxam

Grünenthal capitalizes on Axxam’s drug discovery platform and expertise to identify small molecule lead structures for its early pipeline in pain and inflammation

Grünenthal and Axxam announced today that they have entered into an integrated collaboration. The objective is to discover novel small molecule lead structures for the development of pain and inflammation therapeutics by combining Axxam’s drug discovery platform with Grünenthal’s expertise on emerging and innovative biological pathways and targets.

More ...

next [4]